A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)
A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple…
read more